Triple-negative breast cancer: Clinical and histological correlations

Breast Care

Volumn 6, Issue 4, 2011, Pages 273-278

  Elsawaf, Zeinab ^a   Sinn, Hans Peter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Breast cancer; molecular subtypes

Indexed keywords

BRCA1 PROTEIN; CLAUDIN; CYCLIN E; CYCLINE; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN P16;

APOCRINE CARCINOMA; BRAIN METASTASIS; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; GENE AMPLIFICATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; LUNG METASTASIS; MEDULLARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; VISCERAL METASTASIS;

EID: 80052883297     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000331643     Document Type: Review

References (86)

1. Tavassoli FA, Devilee P: Tumours of the breast and female genital organs. Pathology and Genetics. Lyon, IARC Press, 2003.
2. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874. (Pubitemid 32878711)
3. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, de Jong D, Van de Vijver MJ, Van't Veer LJ, Peterse JL: Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008;216:141-150.
4. Perou CM: Molecular stratification of triplenegative breast cancers. Oncologist 2010;15(suppl 5):39-48.
5. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA: Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-4434. (Pubitemid 47219710)
6. Bosch A, Eroles P, Zaragoza R, Vina JR, Lluch A: Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 2010;36:206-215.
7. Rakha E, Elsheikh S, Aleskandarany M, Habashi H, Green A, Powe D, El-Sayed M, Benhasouna A, Brunet J, Akslen L, Evans A, Blamey R, Reis-Filho J, Foulkes W, Ellis I: Triple-negative breast cancer: Distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009;15:2302-2310.
8. Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P, Birnbaum D: How basal are triple-negative breast cancers? Int J Cancer 2008;123:236-240. (Pubitemid 351705215)
9. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007;9:R65.
10. Bidard FC, Conforti R, Boulet T, Michiels S, Delaloge S, Andre F: Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triplenegative' breast cancers. Ann Oncol 2007;18:1285-1286. (Pubitemid 47244379)
11. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006;24:5652-5657. (Pubitemid 46631305)
12. Carey L, Dees E, Sawyer L, Gatti L, Moore D, Collichio F, Ollila D, Sartor C, Graham M, Perou C: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-2334. (Pubitemid 46698581)
13. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32. (Pubitemid 46120191)
14. Reis-Filho JS, Tutt AN: Triple negative tumours: A critical review. Histopathology 2008;52:108-118. (Pubitemid 350265179)
15. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA: Triple-negative breast cancer: Risk factors to potential targets. Clin Cancer Res 2008;14:8010-8018.
16. Bauer K, Brown M, Cress R, Parise C, Caggiano V: Descriptive analysis of estrogen receptor (ER) - negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A populationbased study from the California Cancer Registry. Cancer 2007;109:1721-1728. (Pubitemid 46668532)
17. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, Mitchell EP: Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: A single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results Database. Cancer 2007;110:876-884. (Pubitemid 47257667)
18. Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA: Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: Age-specific prevalence and survival. J Surg Res 2007;143:109-118. (Pubitemid 47562451)
19. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD: Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007;7:134.
20. Bowen RL, Duffy SW, Ryan DA, Hart IR, Jones JL: Early onset of breast cancer in a group of British black women. Br J Cancer 2008;98:277-281. (Pubitemid 351161260)
21. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW: Race and triple negative threats to breast cancer survival: A population-based study in Atlanta, GA. Breast Cancer Res Treat 2009;113:357-370.
22. Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW: The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009;20:1071-1082.
23. Shinde SS, Forman MR, Kuerer HM, Yan K, Peintinger F, Hunt KK, Hortobagyi GN, Pusztai L, Symmans WF: Higher parity and shorter breastfeeding duration: Association with triple-negative phenotype of breast cancer. Cancer 2010;116:4933-4943.
24. Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, Malone KE: Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 2009;18:1157-1166.
25. Tot T: The cytokeratin profile of medullary carcinoma of the breast. Histopathology 2000;37:175-181. (Pubitemid 30608517)
26. Fulford L, Easton D, Reis-Filho J, Sofronis A, Gillett C, Lakhani S, Hanby A: Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006;49:22-34. (Pubitemid 43972917)
27. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-271. (Pubitemid 43117611)
28. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM: Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008;109:123-139. (Pubitemid 351538762)
29. Sasa M, Bando Y, Takahashi M, Hirose T, Nagao T: Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer. J Surg Oncol 2008;97:30-34.
30. Kaplan HG, Malmgren JA, Atwood M: T1N0 triple negative breast cancer: Risk of recurrence and adjuvant chemotherapy. Breast J 2009;15:454-460.
31. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-2502. (Pubitemid 43854964)
32. Jacquemier J, Padovani L, Rabayrol L, Lakhani SR, Penault-Llorca F, Denoux Y, Fiche M, Figueiro P, Maisongrosse V, Ledoussal V, Martinez Penuela J, Udvarhely N, El Makdissi G, Ginestier C, Geneix J, Charafe-Jauffret E, Xerri L, Eisinger F, Birnbaum D, Sobol H: Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 2005;207:260-268. (Pubitemid 41556449)
33. Reis-Filho JS, Milanezi F, Steele D, Savage K, Simpson PT, Nesland JM, Pereira EM, Lakhani SR, Schmitt FC: Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006;49:10-21. (Pubitemid 43972916)
34. Cleator S, Heller W, Coombes R: Triple-negative breast cancer: Therapeutic options. Lancet Oncol 2007;8:235-244. (Pubitemid 46291713)
35. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adelaide J, Debono S, Houvenaeghel G, Maraninchi D, Viens P, Charpin C, Jacquemier J, Birnbaum D: Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 2006;66:4636-4644.
36. Rodriguez-Pinilla SM, Rodriguez-Gil Y, Moreno-Bueno G, Sarrio D, Martin-Guijarro Mdel C, Hernandez L, Palacios J: Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: An immunohistochemical and gene amplification study. Am J Surg Pathol 2007;31:501-508. (Pubitemid 46569033)
37. Rakha E, Tan D, Foulkes W, Ellis I, Tutt A, Nielsen T, Reis-Filho J: Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer Res 2007;9:404; author reply 405.
38. Rakha EA, Ellis IO, Reis-Filho JS: Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and HER2/neu (basal-like breast carcinomas). Mod Pathol 2008;21:1060-1061; author reply 1061-1062.
39. Calza S, Hall P, Auer G, Bjohle J, Klaar S, Kronenwett U, Liu ET, Miller L, Ploner A, Smeds J, Bergh J, Pawitan Y: Intrinsic molecular signature of breast cancer in a populationbased cohort of 412 patients. Breast Cancer Res 2006;8:R34.
40. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahl PO, Lundin M, Krogh M, Kataja P, Borg A, Ferno M, Isola J: Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 2007;9:R16.
41. Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchio C, Reis-Filho JS: Breast cancer precursors revisited: Molecular features and progression pathways. Histopathology 2010;57:171-192.
42. Banneau G, Guedj M, MacGrogan G, de Mascarel I, Velasco V, Schiappa R, Bonadona V, David A, Dugast C, Gilbert-Dussardier B, Ingster O, Vabres P, Caux F, de Reynies A, Iggo R, Sevenet N, Bonnet F, Longy M: Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations. Breast Cancer Res 2010;12:R63.
43. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Koechli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, Brown P: Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-1996. (Pubitemid 35434844)
44. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI, Ellis IO: Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004;203:661-671. (Pubitemid 38714103)
45. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-8423. (Pubitemid 36842560)
46. Tan D, Marchió C, Jones R, Savage K, Smith I, Dowsett M, Reis-Filho J: Triple negative breast cancer: Molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008;111:27-44. (Pubitemid 352009225)
47. Kuroda N, Ohara M, Inoue K, Mizuno K, Fujishima N, Hamaguchi N, Lee GH: The majority of triple-negative breast cancer may correspond to basal-like carcinoma, but triple-negative breast cancer is not identical to basal-like carcinoma. Med Mol Morphol 2009;42:128-131.
48. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 2000;406:747-752.
49. Böcker W, Moll R, Poremba C, Holland R, Van Diest P, Dervan P, Bürger H, Wai D, Ina Diallo R, Brandt B, Herbst H, Schmidt A, Lerch M, Buchwallow I: Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: A new cell biological concept. Lab Invest 2002;82:737-746.
50. Clayton H, Titley I, Vivanco M: Growth and differentiation of progenitor/stem cells derived from the human mammary gland. Exp Cell Res 2004;297:444-460. (Pubitemid 38798406)
51. Tsuda H, Morita D, Kimura M, Shinto E, Ohtsuka Y, Matsubara O, Inazawa J, Tamaki K, Mochizuki H, Tamai S, Hiraide H: Correlation of Kit and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. Cancer Sci 2005;96:48-53. (Pubitemid 40310025)
52. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F: p63, cytokeratin 5, and P-cadherin: Three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 2005;447:688-694. (Pubitemid 41571183)
53. Foulkes W, Brunet J, Stefansson I, Straume O, Chappuis P, Bégin L, Hamel N, Goffin J, Wong N, Trudel M, Kapusta L, Porter P, Akslen L: The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/ glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004;64:830-835. (Pubitemid 38176880)
54. Jones C, Ford E, Gillett C, Ryder K, Merrett S, Reis-Filho JS, Fulford LG, Hanby A, Lakhani SR: Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res 2004;10:5988-5997. (Pubitemid 39287503)
55. Bankfalvi A, Ludwig A, De-Hesselle B, Buerger H, Buchwalow IB, Böcker W: Different proliferative activity of the glandular and myoepithelial lineages in benign proliferative and early malignant breast diseases. Mod Pathol 2004;17:1051-1061. (Pubitemid 39128231)
56. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-5374. (Pubitemid 39100473)
57. Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J, van Diest P, Brandt B, Boecker W, Buerger H: Cytogenetic alterations and cytokeratin expression patterns in breast cancer: Integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002;82:1525-1533. (Pubitemid 35332911)
58. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO: High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005;116:340-350. (Pubitemid 40993329)
59. Troester MA, Herschkowitz JI, Oh DS, He X, Hoadley KA, Barbier CS, Perou CM: Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 2006;6:276.
60. Dogu GG, Ozkan M, Ozturk F, Dikilitas M, Er O, Ozturk A: Triple-negative breast cancer: Immunohistochemical correlation with basaloid markers and prognostic value of survivin. Med Oncol 2010;27:34-39.
61. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003;95:1482-1485. (Pubitemid 37279334)
62. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003;100:10393-10398. (Pubitemid 37071889)
63. Gusterson B, Ross D, Heath V, Stein T: Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 2005;7:143-148. (Pubitemid 40872776)
64. Potemski P, Kusinska R, Watala C, Pluciennik E, Bednarek A, Kordek R: Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology 2005;69:478-485.
65. Narod SA, Foulkes WD: BRCA1 and BRCA2:1994 and beyond. Nat Rev Cancer 2004;4:665-676.
66. Friedenson B: The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. BMC Cancer 2007;7:152.
67. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Kramling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JG, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, Jacquemier J, Wagner T, Peto J, Stratton MR, McGuffog L, Easton DF: Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005;11:5175-5180. (Pubitemid 41003703)
68. van der Groep P, Bouter A, van der Zanden R, Siccama I, Menko FH, Gille JJ, van Kalken C, van der Wall E, Verheijen RH, van Diest PJ: Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. J Clin Pathol 2006;59:611-617. (Pubitemid 43886045)
69. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK: Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008;26:4282-4288.
70. Crook T, Brooks LA, Crossland S, Osin P, Barker KT, Waller J, Philp E, Smith PD, Yulug I, Peto J, Parker G, Allday MJ, Crompton MR, Gusterson BA: p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1-and BRCA2-associated breast tumours. Oncogene 1998;17:1681-1689. (Pubitemid 28482645)
71. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-819. (Pubitemid 39331153)
72. Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J, Brooks KA, Cohen S, Tenenholz B, Desai D, Zandvakili I, Royer R, Li S, Narod SA: The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 2009;9:86.
73. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, Wilfond B, Borg A, Trent J, Raffeld M, Yakhini Z, Ben-Dor A, Dougherty E, Kononen J, Bubendorf L, Fehrle W, Pittaluga S, Gruvberger S, Loman N, Johannsson O, Olsson H, Sauter G: Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001;344:539-548. (Pubitemid 32167867)
74. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, Savage K, Gillett CE, Schmitt FC, Ashworth A, Tutt AN: BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007;26:2126-2132. (Pubitemid 46514749)
75. Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, Anders C, Ewend M, Perou CM: Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat 2011, in press.
76. Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A, du Bois A: Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 2009;45:2792-2798.
77. Fulford L, Reis-Filho J, Ryder K, Jones C, Gillett C, Hanby A, Easton D, Lakhani S: Basallike grade III invasive ductal carcinoma of the breast: Patterns of metastasis and long-term survival. Breast Cancer Res 2007;9:R4.
78. Hicks DG, Short SM, Prescott NL, Tarr SM, Coleman KA, Yoder BJ, Crowe JP, Choueiri TK, Dawson AE, Budd GT, Tubbs RR, Casey G, Weil RJ: Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006;30:1097-1104. (Pubitemid 44299342)
79. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004;22:2865-2872. (Pubitemid 41079905)
80. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA: Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 2009;115:423-428.
81. Tsuda H, Takarabe T, Hasegawa F, Fukutomi T, Hirohashi S: Large, central acellular zones indicating myoepithelial tumor differentiation in highgrade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 2000;24:197-202. (Pubitemid 30078708)
82. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-1167.
83. Harris L, Broadwater G, Lin N, Miron A, Schnitt S, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes D, Winer E, Dressler L: Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: Results from CALGB 9342. Breast Cancer Res 2006;8:R66.
84. Liu ZB, Wu J, Ping B, Feng LQ, Di GH, Lu JS, Shen KW, Shen ZZ, Shaol ZM: Basal cytokeratin expression in relation to immunohistochemical and clinical characterization in breast cancer patients with triple negative phenotype. Tumori 2009;95:53-62.
85. Lund MJ, Butler EN, Bumpers HL, Okoli J, Rizzo M, Hatchett N, Green VL, Brawley OW, Oprea-Ilies GM, Gabram SG: High prevalence of triple-negative tumors in an urban cancer center. Cancer 2008;113:608-615.
86. Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AH, Robertson JF, Blamey RW, Macmillan D, Ellis IO: Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 2006;42:3149-3156. (Pubitemid 44854512)